BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 20630554)

  • 1. Structural characterization of the Hepatitis C Virus NS3 protease from genotype 3a: the basis of the genotype 1b vs. 3a inhibitor potency shift.
    Gallo M; Bottomley MJ; Pennestri M; Eliseo T; Paci M; Koch U; Bazzo R; Summa V; Carfì A; Cicero DO
    Virology; 2010 Sep; 405(2):424-38. PubMed ID: 20630554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins.
    Massariol MJ; Zhao S; Marquis M; Thibeault D; White PW
    Biochem Biophys Res Commun; 2010 Jan; 391(1):692-7. PubMed ID: 19944069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of the fused NS4A peptide-NS3 protease domain to study the importance of the helicase domain for protease inhibitor binding to hepatitis C virus NS3-NS4A.
    Thibeault D; Massariol MJ; Zhao S; Welchner E; Goudreau N; Gingras R; Llinàs-Brunet M; White PW
    Biochemistry; 2009 Feb; 48(4):744-53. PubMed ID: 19119853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
    López-Labrador FX; Moya A; Gonzàlez-Candelas F
    Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel macrocyclic inhibitors of hepatitis C NS3/4A protease featuring a 2-amino-1,3-thiazole as a P4 carbamate replacement.
    Di Francesco ME; Dessole G; Nizi E; Pace P; Koch U; Fiore F; Pesci S; Di Muzio J; Monteagudo E; Rowley M; Summa V
    J Med Chem; 2009 Nov; 52(22):7014-28. PubMed ID: 19856919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanistic and kinetic characterization of hepatitis C virus NS3 protein interactions with NS4A and protease inhibitors.
    Geitmann M; Dahl G; Danielson UH
    J Mol Recognit; 2011; 24(1):60-70. PubMed ID: 21194118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals.
    Franco S; Clotet B; Martínez MA
    Virus Res; 2008 Feb; 131(2):260-70. PubMed ID: 18037183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061.
    Thibeault D; Bousquet C; Gingras R; Lagacé L; Maurice R; White PW; Lamarre D
    J Virol; 2004 Jul; 78(14):7352-9. PubMed ID: 15220408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
    Tsantrizos YS
    Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel potent macrocyclic inhibitors of the hepatitis C virus NS3 protease: use of cyclopentane and cyclopentene P2-motifs.
    Bäck M; Johansson PO; Wångsell F; Thorstensson F; Kvarnström I; Ayesa S; Wähling H; Pelcman M; Jansson K; Lindström S; Wallberg H; Classon B; Rydergård C; Vrang L; Hamelink E; Hallberg A; Rosenquist S; Samuelsson B
    Bioorg Med Chem; 2007 Nov; 15(22):7184-202. PubMed ID: 17845856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus.
    Lodrini S; Bagaglio S; Canducci F; De Mitri MS; Andreone P; Loggi E; Lazzarin A; Clementi M; Morsica G
    J Biol Regul Homeost Agents; 2003; 17(2):198-204. PubMed ID: 14518724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors.
    Avolio S; Robertson K; Hernando JI; DiMuzio J; Summa V
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2295-8. PubMed ID: 19285390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A protease.
    Rudd MT; McCauley JA; Romano JJ; Butcher JW; Bush K; McIntyre CJ; Nguyen KT; Gilbert KF; Lyle TA; Holloway MK; Wan BL; Vacca JP; Summa V; Harper S; Rowley M; Carroll SS; Burlein C; DiMuzio JM; Gates A; Graham DJ; Huang Q; Ludmerer SW; McClain S; McHale C; Stahlhut M; Fandozzi C; Taylor A; Trainor N; Olsen DB; Liverton NJ
    Bioorg Med Chem Lett; 2012 Dec; 22(23):7201-6. PubMed ID: 23021993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2-P4 linkers.
    Rudd MT; McIntyre CJ; Romano JJ; Butcher JW; Holloway MK; Bush K; Nguyen KT; Gilbert KF; Lyle TA; Liverton NJ; Wan BL; Summa V; Harper S; Rowley M; Vacca JP; Carroll SS; Burlein C; DiMuzio JM; Gates A; Graham DJ; Huang Q; Ludmerer SW; McClain S; McHale C; Stahlhut M; Fandozzi C; Taylor A; Trainor N; Olsen DB; McCauley JA
    Bioorg Med Chem Lett; 2012 Dec; 22(23):7207-13. PubMed ID: 23084906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of robust in vitro serine protease assay based on recombinant Pakistani HCV NS3-4A protease.
    Fatima K; Tahir M; Qadri I
    Virus Res; 2011 Sep; 160(1-2):230-7. PubMed ID: 21756947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
    Dahl G; Sandström A; Akerblom E; Danielson UH
    Antivir Ther; 2007; 12(5):733-40. PubMed ID: 17713156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition and binding kinetics of the hepatitis C virus NS3 protease inhibitor ITMN-191 reveals tight binding and slow dissociative behavior.
    Rajagopalan R; Misialek S; Stevens SK; Myszka DG; Brandhuber BJ; Ballard JA; Andrews SW; Seiwert SD; Kossen K
    Biochemistry; 2009 Mar; 48(11):2559-68. PubMed ID: 19209850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bismacrocyclic inhibitors of hepatitis C NS3/4a protease.
    McCauley JA; Rudd MT; Nguyen KT; McIntyre CJ; Romano JJ; Bush KJ; Varga SL; Ross CW; Carroll SS; DiMuzio J; Stahlhut MW; Olsen DB; Lyle TA; Vacca JP; Liverton NJ
    Angew Chem Int Ed Engl; 2008; 47(47):9104-7. PubMed ID: 18925594
    [No Abstract]   [Full Text] [Related]  

  • 19. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease.
    Liverton NJ; Holloway MK; McCauley JA; Rudd MT; Butcher JW; Carroll SS; DiMuzio J; Fandozzi C; Gilbert KF; Mao SS; McIntyre CJ; Nguyen KT; Romano JJ; Stahlhut M; Wan BL; Olsen DB; Vacca JP
    J Am Chem Soc; 2008 Apr; 130(14):4607-9. PubMed ID: 18338894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solution structure and dynamics of the single-chain hepatitis C virus NS3 protease NS4A cofactor complex.
    McCoy MA; Senior MM; Gesell JJ; Ramanathan L; Wyss DF
    J Mol Biol; 2001 Feb; 305(5):1099-110. PubMed ID: 11162117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.